Evidence map›Paper›PMID 40889269›Full record

ArticleJournal of visualized experiments : JoVE2025

Development of Drug-resistant Cell Lines for Experimental Procedures.

Suguru Kadomoto, Greg Shelley, Atsushi Mizokami, Evan T Keller

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Suguru KadomotoDepartment of Urology, University of Michigan, Ann Arbor; Department of Urology, Kanazawa University.
Greg ShelleyDepartment of Urology, University of Michigan, Ann Arbor.
Atsushi MizokamiDepartment of Urology, Kanazawa University.
Evan T KellerDepartment of Urology, University of Michigan, Ann Arbor; Biointerfaces Institute, University of Michigan, Ann Arbor; Single Cell Spatial Analysis Program, University of Michigan, Ann Arbor; etkeller@med.umich.edu.

Funding

Tumor microvesicle-mediated modulation of the bone microenvironmentP01CA093900 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KELLER, EVAN T · 2004 to 2024
$29.6M
NCI NIH HHS P01 CA093900
6 · The paper itself

Abstract

The development of drug-resistant cell lines is essential for understanding the mechanisms of drug resistance and identifying strategies to overcome treatment failure in cancer therapy. Resistance models enable preclinical evaluation of novel compounds, repurposed drugs, and combination therapies. To generate resistant cells, parental cancer cell lines are repeatedly exposed to incrementally increasing concentrations of the target drug over several weeks. Cells that survive and proliferate at each stage are selected, expanded, and exposed to higher drug doses. The development of resistance is confirmed by quantifying and comparing the half-maximal inhibitory concentration (IC50) values between parental and resistant cells using cell viability assays and nonlinear regression analysis. Significantly increased IC50 values indicate successful adaptation to drug pressure and the development of resistance. These drug-resistant cell lines are available for comprehensive analysis, such as microarray and single-cell sequencing, as well as various in vitro or in vivo experiments. These models provide valuable tools for investigating potential therapeutic strategies to overcome drug resistance.

Indexed as

Antineoplastic AgentsDrug Resistance, NeoplasmCell Line, TumorCell SurvivalHumansAntineoplastic Agents

Identifiers

PMID40889269
PMCPMC12404681

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.